|
|
News Breaks
|
November 28, 2011
|
| 09:07 EDT |  | PRAN |
| theflyonthewall.com: | Prana secures key patent for Parkinson's drug PBT434 in the U.S. | | Prana Biotechnology announced that the United States Patent and Trademark Office, USPTO, has issued a Notice of Allowance for a composition of matter patent for selected 8-hydroxy quinazolinone compounds, including its lead Parkinson's Disease, PD, drug candidate, PBT434, in the United States. The patent entitled 'Neurologically Active Compounds' also covers pharmaceutical compositions containing PBT434 and selected 8-hydroxy quinazolinone compounds. Once granted, the United States patent has a twenty year term expiring June 7, 2026. This expiry date may in the future be further extended by the application of pharmaceutical extension of term provisions of up to five years in the United States. Geoffrey Kempler, Prana's CEO, said, "Securing granted rights to our lead PD drug candidate furthers our commercialization :theflyonthewall.com |
|
|
News For PRAN From The Last 14 Days Check below for free stories on PRAN the last two weeks.
| Sign up for a free trial to see the rest of the stories you've been missing. |
There are no results for these search parameters.
|
|
|
|
